ERBB2 Recombinant Proteins
ERBB2, also known as HER2 (Human Epidermal Growth Factor Receptor 2), is a member of the ERBB family of receptor tyrosine kinases. It plays a crucial role in cellular growth, differentiation, and repair mechanisms. Overexpression of ERBB2 is associated with aggressive cancers, particularly breast and gastric cancers.
Content on ERBB2 Recombinant Proteins
ERBB2 recombinant proteins are typically expressed in advanced systems like mammalian or bacterial cells to ensure proper folding and post-translational modifications. Key attributes include:
- Structure: Available as extracellular domains, intracellular kinase domains, or full-length proteins, often with tags (e.g., His, Fc) for purification and detection.
- Purity: High purity levels (>95%), confirmed through SDS-PAGE and HPLC analysis.
- Bioactivity: Retains receptor-ligand interactions, phosphorylation activity (kinase domain), or antibody-binding capacity (extracellular domain).
Applications of ERBB2 Recombinant Proteins
- Cancer Research:
- Studies the role of HER2 in tumor growth and progression.
- Used in experiments investigating HER2-mediated signaling pathways.
- Therapeutic Antibody Development:
- Serves as a target for developing monoclonal antibodies like trastuzumab and pertuzumab.
- Validates the specificity and binding affinity of therapeutic candidates.
- Functional Assays:
- Applied in receptor-ligand interaction studies and phosphorylation assays to analyze kinase activity.
- Used in cell-based assays to assess downstream signaling activation.
- Drug Screening:
- Facilitates the discovery and evaluation of HER2 inhibitors, such as small molecules and monoclonal antibodies.
ERBB2 recombinant proteins are indispensable for advancing research into HER2-driven cancers and the development of targeted therapies. Their high-quality production ensures reliability and consistency in applications ranging from functional assays to therapeutic discovery, making them critical tools in cancer biology and translational research.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|